US EditionGLP-1 Drugs Ozempic and Wegovy Linked to Lower Anxiety and Depression Risks
A Swedish register study found semaglutide linked to 44% lower depression risk and 38% lower anxiety risk in patients with existing mental health conditions.
- On Wednesday, The Lancet Psychiatry published a study showing semaglutide and liraglutide were associated with lower risk of worsening mental illness using Swedish national health registers and nearly 100,000 participants.
- Because metabolic and mental disorders are linked, the team sought to test whether diabetes and obesity drugs affect mental health, involving the University of Eastern Finland, Karolinska Institutet and Griffith University.
- Semaglutide use was associated with a 44% lower risk of worsening depression, a 38% lower risk of worsening anxiety, and 47% lower hospital care for substance use disorders, while GLP-1 receptor agonists reduced suicidal behaviour risk.
- Authors caution that the study is observational and database limitations include no ethnicity, symptom severity, weight or diabetes markers; earlier pharmacovigilance reports raised safety signals but later evidence is reassuring.
- Researchers note possible neurobiological mechanisms such as insulin and reward-system hypotheses, while experts find the results reassuring and call for future clinical trials to explore pharmacological heterogeneity.
22 Articles
22 Articles
Faced with the initial side effects that were pointed out at the beginning of the boom of these antiobesity drugs, such as their association with suicide, a study with more than 20,000 people shows the opposite: there is a positive impact on the mood Read
Sky News UK
Great Yorkshire RadioWeight loss jabs may help with anxiety and depression, study finds
Researchers found taking weight loss jabs was linked to a lower risk of mental health problems, including a 44% decreased risk of worsening depression associated with one type of drug.
Daily Post
Ozempic and Wegovy found to reduce symptoms of anxiety and depression
Semaglutide is associated with a 44% decreased risk of depression and a 38% decreased risk of anxiety
GLP-1 medications used to treat diabetes and obesity may also help alleviate symptoms of ...
Kuopio, Finland, March 19, 2026 (GLOBE NEWSWIRE) -- GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, a new study shows. The large register-based study…
Coverage Details
Bias Distribution
- 54% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
